Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 39Brain Neoplasms 17Astrocytoma 16Central Nervous System Neoplasms 9Oligodendroglioma 8Gliosarcoma 8Melanoma 7Glioma 7Neoplasms 5Recurrence 4Neoplasm Metastasis 3Neuroblastoma 2Ganglioneuroblastoma 2Diffuse Intrinsic Pontine Glioma 2Choroid Plexus Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Ewing 1Sarcoma 1Rhabdoid Tumor 1Rare Diseases 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Neuroepithelial 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms, Bone Tissue 1Neoplasms by Histologic Type 1Melanoma, Cutaneous Malignant 1

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Malignancies × Temozolomide × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡